Tranzactioneaza Salarius Pharmaceuticals (US.SLRX) - 0.6706 USD (%) Tranzactioneaza
Indici
Descriere companie
Salarius Pharmaceuticals, Inc. (http://salariuspharma.com/) is a clinical-stage biotechnology company focused on developing epigenetic-based cancer treatments. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead product candidate, Seclidemstat (SP-2577), is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1). SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression. The Company is also developing SP-2577 for several cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.